An osteoporosis regimen may benefit the heart as well as the bones.
Reference1. Ohmura K, Kato M, Watanabe T, et al. Effect of combined treatment with bisphosphonate and vitamin D on atherosclerosis in patients with systemic lupus erythematosus: a propensity score-based analysis. Arthritis Res Ther. 2018;20:72. doi: 10.1186/s13075-018-1589-9.
Ohmura and colleagues in Japan found that the prevalence of carotid plaque was significantly lower in patients with lupus who were receiving bisphosphonates and vitamin D as a part of an osteoporosis regimen than in those who were receiving one or the other.1
Scroll through the slides for the details of the study and the take-home points for clinicians.
(Image credit: ©Filipchuk Oleg/Shutterstock.com)
Cardiovascular disease has replaced lupus-related organ failure as the primary cause of morbidity and mortality in SLE.
Of the 72 patients receiving bisphosphonates, 58 (81%) were taking alendronate, 7 (10%) risedronate, 6 (8%) minodronate, and 1 (1%) ibandronate.